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OBJECTIVES The objectives of the current study were to define for the first time the roles of the natriuretic
peptide (NP) receptors and neutral endopeptidase (NEP) in mediating and modulating the
renal actions of Dendroaspis natriuretic peptide (DNP), a new therapeutic synthetic NP.
BACKGROUND Recent reports have advanced the therapeutic potential of a newly described synthetic NP
called DNP. Dendroaspis natriuretic peptide is a 38-amino acid peptide recently isolated
from the venom of Dendroaspis augusticeps (the green mamba snake).
METHODS Synthetic DNP was administered intra-renally at 5 ng/kg/min to 11 normal anesthetized
dogs, 5 of which received the NP receptor antagonist HS-142-1 (3 mg/kg intravenous bolus)
while the remaining 6 dogs received an infusion of the NEP inhibitor, candoxatrilat (8 and
80 g/kg/min) (Pfizer, Sandwich United Kingdom).
RESULTS Intra-renal DNP resulted in marked natriuresis associated with increased urinary cyclic
guanosine monophosphate excretion (UcGMPV), glomerular filtration rate (GFR), and renal
blood flow (RBF) and decreased distal fractional sodium reabsorption (FNaR) compared with
baseline. HS-142-1 attenuated the natriuretic response to DNP, resulting in decreased
UcGMPV, GFR, and RBF and increased distal FNaR. In contrast, low and high doses of
NEP inhibitor did not potentiate the renal actions of DNP.
CONCLUSIONS We report that the NP receptor blockade attenuated the renal actions of synthetic DNP and
that the NEP inhibitor did not alter the renal response to DNP. This latter finding is a unique
property of synthetic DNP, as distinguished from other known NPs, supporting its potential
as a therapeutic agent. (J Am Coll Cardiol 2002;40:1186–91) © 2002 by the American
College of Cardiology Foundation
Recent reports have advanced the therapeutic potential of a
newly described synthetic natriuretic peptide called Den-
droaspis natriuretic peptide (DNP) in the treatment of
congestive heart failure (CHF) (1). Specifically, we have
reported that intravenous infusion of DNP in experimental
CHF increased the glomerular filtration rate (GFR) and
sodium excretion despite reductions in arterial pressure.
Synthetic DNP also increased plasma and urinary cyclic
guanosine monophosphate (cGMP) and suppressed plasma
renin activity. These renal and humoral actions of synthetic
DNP also were associated with decreases in markedly
elevated cardiac filling pressures. These properties of syn-
thetic DNP suggest unique characteristics that support its
development as a new intravenous agent for acutely decom-
pensated CHF (1). Recent studies have also reported that
synthetic DNP is a potent antiproliferative peptide and is
also diuretic when infused directly into the brain (2,3).
Synthetic DNP was designed based on the sequence of
the DNP originally isolated from venom of Dendroaspis
augusticeps (the green mamba snake) (4). Synthetic DNP is
a 38-amino-acid peptide that contains, similar to atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP),
and C-type natriuretic peptide (CNP), a 17-amino-acid
disulfide ring structure with a 15-amino-acid residue
C-terminal extension (Fig. 1). This peptide potently vasore-
laxes isolated precontracted rodent aorta and canine coro-
nary arteries and augments the formation of 35 cGMP in
aortic endothelial and vascular smooth muscle cells (4,5).
Dendroaspis natriuretic peptide has an extended
C-terminus, which may result in greater resistance to
peptide degradation in the kidney by neutral endopeptidase
(NEP). In addition, although it is synthetic and without
significant homology to the other known natriuretic pep-
tides, the increases in plasma and urinary cGMP in response
to synthetic DNP suggests an interaction with the known
natriuretic peptide particulate-guanylyl-cyclase receptors.
The goal of the current study was to extend previous
studies and provide insight into the interactions of synthetic
DNP with natriuretic peptide receptors and NEP. First, we
sought to define an interaction between synthetic DNP and
the natriuretic peptide particulate-guanylyl-cyclase recep-
tors in mediating the renal actions of this new synthetic
natriuretic peptide. This was accomplished by intra-renal
administration of synthetic DNP in the presence of intra-
venous administration of the particulate-guanylyl-cyclase
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receptor antagonist HS-142-1 (HS), which is known to
block the renal actions of ANP and BNP (6). HS-142-1 is
a novel polysaccharide isolated from culture broth of Aureo-
basidium sp., which competitively and selectively inhibited
ANP binding to its guanylyl-cyclase-containing blocked
cGMP production elicited by ANP (7). We hypothesized
that HS-142-1 would attenuate the renal actions of syn-
thetic DNP. Our second goal was to demonstrate that
synthetic DNP in vivo is resistant to degradation by NEP.
To address this objective, DNP was administered in the
presence and absence of low- and high-dose administration
of the potent NEP inhibitor candoxatrilat. We hypothe-
sized that the renal actions of DNP would not be potenti-
ated by NEP inhibition. We found that natriuretic peptide
receptor blockade attenuated the renal actions of synthetic
DNP and that NEP inhibition did not alter the renal
response to DNP. This latter finding is a unique property of
synthetic DNP, as distinguished from other known natri-
uretic peptides, supporting its potential as a therapeutic
agent.
METHODS
Studies were performed in 11 male mongrel dogs weighing
between 20 and 25 kg. The dogs were maintained on a
normal sodium diet with standard dog chow (Lab Canine
Diet 5006; Purina Mills, St. Louis, Missouri) with free
access to tap water. All studies conformed to the guidelines
of the American Physiological Society and were approved by
the Mayo Clinic Institutional Animal Care and Use Com-
mittee.
Experimental protocol. On the evening before the exper-
iment, 300 mg of lithium carbonate was administered orally
for the assessment of renal tubular function. On the day of
the basic experiment, the dogs were anesthetized with
sodium pentobarbital (15 mg/kg intravenous), intubated,
and mechanically ventilated with supplemental oxygen
(Harvard respirator, Amersham, Massachusetts) at 16 cy-
cles/min. The femoral artery was cannulated for blood
pressure monitoring and blood sampling. The femoral vein
was also cannulated for normal saline infusion. The left
kidney was exposed via a flank incision, and the ureter was
cannulated for urine collection. A calibrated noncannulating
electromagnetic flow probe was place around the renal artery
for continuous monitoring of renal blood flow (RBF). In
addition, a curved 23-gauge needle, attached to polyethyl-
ene tubing, was inserted into the renal artery proximal to the
flow probe for intra-renal infusion of synthetic DNP (DNP
1-38, Phoenix Pharmaceuticals Inc., Mountain View, Cal-
ifornia). Furthermore, a curved 23-gauge needle attached to
polyethylene tubing was inserted into the renal vein for
collection of venous blood. Supplemental nonhypotensive
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
cGMP  cyclic guanosine monophosphate
CHF  congestive heart failure
CLLi  lithium clearance
CLNa  sodium clearance
CNP  C-type natriuretic peptide
DFNaR  distal fractional sodium reabsorption
DNP  Dendroaspis natriuretic peptide
GFR  glomerular filtration rate
MAP  mean arterial blood pressure
NEP  neutral endopeptidase 24-11
RBF  renal blood flow
UcGMPV  urinary cGMP excretion
UNaV  urinary sodium excretion
Figure 1. Amino acid sequence and structure of natriuretic peptides. ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; CNP  C-type
natriuretic peptide; DNP  Dendroaspsis natriuretic peptide.
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doses of pentobarbital sodium were given as needed during
the experiment.
After completion of the surgical preparation, a priming
dose of insulin (ICN Biomedicals, Cleveland, Ohio) dis-
solved in isotonic saline was administered intravenously
followed by a constant infusion of 1 ml/min to achieve a
steady-state plasma inulin concentration between 40 to 60
mg/dl. After an equilibration period of 60 min, a 30-min
baseline clearance was performed; hemodynamic recordings,
plasma, and urine were collected for hormonal determina-
tion. This was followed by a 15-min lead-in period during
which DNP was infused intra-renally at 5 ng/kg/min in all
11 dogs, after which the second 30-min clearance was
performed.
After this second 30-min clearance, five dogs received
intravenous bolus injection of the natriuretic peptide recep-
tor antagonist HS-142-1 3 mg/kg (a gift from Yuzuru
Matsuda, Tokyo Research Laboratories, Kyowa Hakko
Kogyo Co., Japan) in addition to the continuous intra-renal
infusion of DNP. This was followed by four 30-min
clearances.
The remaining six dogs received continuous intravenous
infusion of the NEP inhibitor candoxatrilat (Pfizer) at a
dose of 8 g/kg/min (low dose) in addition to the contin-
uous intra-renal infusion of DNP. After a 15-min lead-in
period, a 30-min clearance was performed, after which the
dose of candoxatrilat was increased to 80 g/kg/min (high
dose), and, after a 15-min lead-in period, another 30-min
clearance was performed. The dose of 80 g/kg/min rep-
resents the peak dose response curve for candoxatrilat
(unpublished data, Pfizer).
Mean arterial blood pressure (MAP) was assessed via
direct measurement from the femoral arterial catheter.
Urine was collected on ice for assessment of urine volume,
electrolytes, and inulin. Urine collected for cGMP analysis
was heated to more than 90°C before storage. Blood was
collected in heparin and ethylene diamine tetra acetate tubes
and immediately placed on ice. After centrifugation at 2,500
rpm at 4°C, plasma was decanted and stored at 20°C until
analysis. The GFR was determined by the clearance of
inulin.
Hormone and electrolyte analysis. After plasma extrac-
tion plasma and urine ANP, BNP, DNP, renin, and cGMP
were measured by radioimmunoassay (5). Urinary and
plasma inulin were measured by the anthrone method.
Urinary and plasma lithium were determined by flame
emission spectrophotometry (model 357, Instrumentation
Laboratory, Wilmington, Massachusetts). Employing the
lithium clearance (CLLi) technique, distal fractional reab-
sorption of sodium (DFNaR) was calculated using the
following equation: DFNaR  [(CLLi  CLNa)/CLLi 
100], where CLLi  [(urine Li  urine flow)/plasma Li]
and CLNa  [(urine Na  urine flow)/plasma Na].
Statistical analysis. Results of the quantitative studies were
expressed as mean  SEM. Data were assessed by repeated
measures analysis of variance for comparisons within
groups, using GraphPad Prism software (GraphPad Soft-
ware Inc., San Diego, California) and post-hoc Dunnett’s
test for multiple comparisons. In the group receiving NEP
inhibition, there were four repeated measures; in the group
receiving HS-142-1, there were six repeated measures.
Statistical significance was accepted as p  0.05.
RESULTS
Renal and humoral actions of intra-renal DNP. Table 1
reports the renal and humoral actions of intra-renal infusion
of DNP (n  11). Mean arterial blood pressure was not
significantly altered with the intra-renal infusion of DNP.
Urinary sodium excretion (UNaV) was significantly in-
creased, associated with a decrease in DFNaR. Both GFR
and renal blood flow increased with the intra-renal infusion
of DNP. Urinary cGMP excretion (UcGMPV) and plasma
cGMP increased, while renal vein renin activity was sup-
pressed with intra-renal infusion of DNP. Both plasma and
urinary ANP and BNP remained unchanged (data not
shown).
Natriuretic peptide receptor antagonist HS-142-1 on
DNP. The effects of HS-142-1, a natriuretic peptide re-
ceptor antagonist on UNaV, DFNaR, GFR, and RBF are
illustrated in Figure 2 (n  5). HS-142-1 attenuated the
natriuretic response (UNaV) to DNP, which was secondary
to a decrease in GFR and RBF and increased DFNaR. The
attenuated renal response to DNP in the presence of HS is
associated with decreases in plasma cGMP and UcGMP,
the second messenger of DNP (Fig. 3), in the absence of any
change in plasma and urinary DNP excretion (data not
shown). Renal vein renin activity increased with HS-142-1,
from 3.8  1 ng/ml/h with DNP alone to 5.3  2 ng/ml/h
(p  0.05) after HS-142-1.
NEP inhibition on DNP. Both low- and high-dose NEP
inhibition did not potentiate the renal actions of DNP.
Urinary sodium excretion, DFNaR, RBF, and GFR re-
mained unchanged with either low-dose or high-dose NEP
inhibitor (Table 2) (n  6). Plasma ANP, BNP, DNP, and
urinary BNP and DNP excretion did not increase with
NEP inhibitor; however, urinary ANP excretion did in-
crease (Table 2). There was a trend for UcGMPV to
Table 1. Renal and Humoral Actions of Intra-Renal DNP
Baseline Intra-Renal DNP
MAP, mm Hg 130  3 126  3
UNaV, Eq/min 67  30 355  41*
DFNaR, % 97  0.8 86  2.8*
GFR, ml/min 33  4 52  5*
RBF, ml/min 285  23 319  17*
UcGMPV, pmol/min 1,012  115 2,033  235*
Plasma cGMP, pmol/ml 11  1 20  1*
Renal vein renin, ng/ml/h 8  1 5  1*
*p  0.05 versus baseline. Mean  SEM.
DFNaR  distal fractional sodium reabsorption; DNP  Dendroaspis natriuretic
peptide; GFR  glomerular filtration rate; MAP  mean arterial blood pressure;
RBF  renal blood flow; UcGMPV  urinary cGMP excretion; UNaV  urinary
sodium excretion.
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increase with NEP inhibition; however, this did not reach
statistical significance (Table 2).
DISCUSSION
Our current findings demonstrate that the natriuretic and
renal hemodynamic actions of synthetic DNP, a potentially
important new therapeutic agent, are attenuated by natri-
uretic peptide receptor antagonism, while NEP inhibition
had no effect. These findings suggest that the biological
actions of DNP are mediated, in part, via the natriuretic
peptide particulate-guanylyl-cyclase receptors and that
DNP is either resistant to degradation by NEP or is not a
substrate at all. The current findings confirm previous
experimental studies establishing that synthetic DNP has
natriuretic, diuretic, renin-inhibiting properties and en-
hances RBF and GFR. More importantly, the current study
extends previous investigations and defines the role of the
natriuretic peptide particulate-guanylyl-cyclase receptors
and NEP in mediating the renal actions of synthetic DNP.
Dendroaspis natriuretic peptide was administered intra-
renally in order to define its renal actions without altering
the MAP. Intra-renal DNP resulted in marked natriuresis,
diuresis which was associated with increases in RBF, GFR,
plasma and urinary cGMP excretion, and a decrease in
distal fractional sodium reabsorption without a change in
renal perfusion pressure. Despite the marked natriuresis and
diuresis, renal vein renin activity was suppressed consistent
with the renin-inhibiting actions of DNP. Furthermore,
plasma and urinary cGMP increased with intra-renal DNP
despite the fact the both plasma and urinary ANP and BNP
were unchanged, therefore confirming that cGMP is indeed
the second messenger of DNP.
HS-142-1 is an antagonist to natriuretic peptide
particulate-guanylyl-cyclase receptors (6). This antagonist,
which has been well-characterized, attenuated the natri-
uretic and diuretic actions of intra-renal DNP and abolished
the increase in RBF and GFR. More importantly, both
plasma and urinary cGMP returned to baseline with HS-
142-1 despite continued intra-renal infusion of DNP,
therefore supporting the conclusion that the renal actions of
DNP are, in part, mediated via the natriuretic peptide
particulate-guanylyl-cyclase receptors producing cGMP as a
second messenger. Of note, HS-142-1 attenuated the na-
triuretic response and the decrease in DFNaR but did not
abolish these actions completely. This may be due to the fact
that these effects may persist for a longer duration as
compared with the second messenger or DNP could also act
on other receptors producing a different second messenger,
which contributes to these actions. Further studies will be
needed to address this issue.
Neutral endopeptidase 24-11 is an ectoenzyme that is
found in abundance in the proximal tubules in the kidney
(8). It metabolizes ANP, BNP, CNP, adrenomedullin,
bradykinin, and other vasoactive peptides (9). Candoxatrilat
Figure 2. Urinary sodium excretion (UNaV), distal tubular fractional reabsorption of sodium (DFNaR), glomerular filtration rate (GFR), and renal blood
flow (RBF) at baseline (open bars), with intra-renal Dendroaspis natriuretic peptide (DNP) infusion alone (hatched bars) and 30, 60, 90, and 120 min
after intravenous bolus administration of HS-142-1 (HS) (solid bars) in addition to continuous intra-renal infusion of DNP. *p  0.05 versus baseline;
p  0.05 versus intra-renal DNP alone.
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is an NEP inhibitor that potentiates the effects of both ANP
and BNP by inhibiting their degradation by NEP. To
ensure that there was adequate inhibition of NEP, we
administered a higher dose of candoxatrilat, 80 g/kg/min,
which represents the peak dose response curve for candox-
atrilat (unpublished data, Pfizer) to ensure that maximum
inhibition was achieved (10).
In the current study, NEP inhibition with low- and
high-dose candoxatrilat did not potentiate the renal actions
of DNP. In contrast, this level of NEP inhibition has been
shown in previous studies to potentiate the renal actions of
exogenous ANP and BNP (8,11). Neither plasma nor
urinary DNP concentration increased with NEP inhibition.
However, urinary ANP excretion was significantly in-
creased, therefore suggesting effective inhibition of NEP.
There was a trend for urinary cGMP excretion to increase
with NEP inhibition; however, this did not reach statistical
significance. The lack of significant increase in UcGMPV
with the NEP inhibitor candoxatrilat in normal dogs,
despite increases in urinary ANP excretion, is consistent
with our previous study (10) where we found similar results.
This is most likely due to the normal baseline ANP level,
which is not activated in normal dogs. Kinetic studies have
shown that the rank order of hydrolysis by NEP is CNP 
ANP  BNP, and it has been suggested that the longer
length of the C-terminus of the peptide results in greater
resistance to hydrolysis by NEP (12). Indeed, BNP has a
longer C-terminus as compared with ANP, which, in turn,
has a longer C-terminus than CNP. Dendroaspis natriuretic
peptide, in contrast, has a 15-residue C-terminus that is
longer when compared with BNP, ANP, and CNP. This
structural difference may explain DNP’s resistance to NEP
degradation. Importantly, this resistance to degradation by
NEP makes synthetic DNP unique among the known
natriuretic peptides and underscores a therapeutic potential
for synthetic DNP, especially in CHF in which NEP has
been reported to be unregulated (13).
Conclusions. The current study is the first to report the
role of the natriuretic peptide particulate-guanylyl-cyclase
receptors and NEP in mediating the renal actions of
synthetic DNP. The natriuretic and renal hemodynamic
actions of DNP are attenuated by HS-142-1, while NEP
inhibition did not potentiate the renal actions of DNP.
These findings support our conclusion that the biological
actions of DNP are mediated, in part, via the natriuretic
Figure 3. Plasma cGMP and urinary cGMP excretion (UcGMPV) at baseline (open bars), with intra-renal Dendroaspis natriuretic peptide (DNP)
infusion alone (hatched bars) and 30, 60, 90, and 120 min after intravenous bolus administration of HS-142-1 (HS) (solid bars) in addition to continuous
intra-renal infusion of DNP. *p  0.05 versus baseline; p  0.05 versus intra-renal DNP alone.
Table 2. Low- and High-Dose NEP Inhibition on DNP
DNP
DNP 
Low-Dose
NEPI
DNP 
High-Dose
NEPI
UNaV, Eq/min 353  61 370  70 374  54
DFNaR, % 85  5 84  5 83  6
GFR, ml/min 53  7 49  3 60  14
RBF, ml/min 335  27 318  23 321  39
Plasma ANP, pg/ml 79  23 74  14 172  78
UANPV, pg/min 24  8 131  53* 365  125*
Plasma DNP, pg/ml 86  43 105  54 108  60
UDNPV, pg/min 160  82 170  60 265  40
Plasma BNP, pg/ml 19  4 22  7 20  4
UBNPV, pg/min 13  8 12  6 13  8
UcGMPV, pmol/min 1,737  244 2,601  384 3,204  628
*p  0.05 versus DNP. Mean  SEM.
DFNaR  distal fractional sodium reabsorption; DNP  Dendroaspis natriuretic
peptide; GFR  glomerular filtration rate; NEP  neutral endopeptidase 24-11;
NEPI neutral endopeptidase 24-11 inhibitor; RBF renal blood flow; UANPV
urinary atrial natriuretic peptide excretion; UBNPV  urinary brain natriuretic
peptide; UcGMP  urinary cGMP excretion; UDNPV  urinary excretion;
UNaV  urinary sodium excretion.
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peptide particulate-guanylyl-cyclase receptors and that
DNP is either resistant to degradation by NEP or not a
substrate at all. These studies also establish the unique
property of DNP, which is its resistance to NEP degrada-
tion, supporting its potential as a therapy for cardiovascular
diseases such as CHF.
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